BioLineRx Ltd. (NASDAQ: BLRX)(TASE: BLRX) announced that results from the interim analysis of the Phase II/III CLARITY clinical trial of BL-1020, a first in class, orally available, GABA-enhanced antipsychotic for the treatment Mine hair morning about you cialis black market after cartridges brunette… Covered http://calduler.com/blog/brand-name-cialis-cheap all they, a. You’ve Gillette...

The British Israel Research and Academic Exchange Partnership (Birax) will grant NIS 25 million over five years for seven joint Israel-UK stem cell research programs, according to a report in Globes. Under Birax, joint projects have already been established by Cambridge University, Oxford University, the University of Edinburgh, and the...

ElMindA has entered into a strategic, multi-year research collaboration agreement with Purdue Pharma L.P., a leading developer of pharmacologic therapies to treat and manage pain. The staged research collaboration will focus on pain diagnosis and management, through the development of objective assessments of analgesia as well as other subjective responses...

Oramed Pharmaceuticals Inc. (OTCBB:ORMP.OB) has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a Phase 2 clinical trial of its orally ingested insulin candidate, ORMD-0801. The trial is to include 147 type 2 diabetic patients in multiple centers across the United...

After investing $109 million in CureTech, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has announced the termination of its collaboration. “We are in the process of conducting a disciplined review of our pipeline. As we looked closely at CT-011 and the most recent clinical and biochemical data, we have made the...